Adherence to Secondary Prevention Guidelines for Cardiovascular Risk

December 10, 2025 updated by: Consorci Sanitari de l'Alt Penedès i Garraf
The present observational study aims to determine the degree of adherence to the recommendations of clinical guidelines regarding the prevention of cardiovascular complications in patients hospitalized due to a cardiovascular event.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

129

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
    • Barcelona
      • Sant Pere de Ribes, Barcelona, Spain, 08810
        • Consorci Sanitari Alt Penedes i Garraf-Hospital Sant Camil

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients hospitalized due to a cardiovascular event

Description

Inclusion Criteria:

  • Admitted to the cardiology, neurology, or general surgery departments
  • With any of the following admission diagnoses:

Non-ST-segment elevation acute coronary syndrome (NSTEACS) ST-segment elevation acute coronary syndrome (STEACS) Stable angina Unstable angina Non-ST-segment elevation myocardial infarction (NSTEMI) ST-segment elevation myocardial infarction (STEMI) Atherothrombotic ischemic stroke Lacunar stroke Peripheral artery disease Chronic ischemia of lower limbs Vascular ulcer due to arterial cause

Exclusion Criteria:

  • Patients for whom lipid-lowering treatment is ruled out due to limited life expectancy
  • Patients likely to die during hospitalization
  • Patients who died during hospitalization

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients hospitalized due to a cardiovascular event
Patients hospitalized due to a cardiovascular event including stroke, acute coronary syndrome, ischemic heart disease, or peripheral arterial disease
Other: cardiovascular event
In this single group observational trial the exposure of interest is a cardiovascular event.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
patients admitted for a cardiovascular event who are prescribed lipid-lowering treatment at discharge
Time Frame: Up to 3 months
Proportion of patients admitted for a cardiovascular event, warranting the initiation of secondary prevention with lipid-lowering agents, who are prescribed lipid-lowering treatment at discharge, adequate to reduce LDL by 50% or to below 55 mg/dL
Up to 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Consorci Sanitari de l'Alt Penedès i Garraf

Investigators

  • Principal Investigator: Lidia Tikhomirova, CSAPG

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2024

Primary Completion (Actual)

September 30, 2025

Study Completion (Actual)

September 30, 2025

Study Registration Dates

First Submitted

June 3, 2024

First Submitted That Met QC Criteria

June 7, 2024

First Posted (Actual)

June 10, 2024

Study Record Updates

Last Update Posted (Actual)

December 17, 2025

Last Update Submitted That Met QC Criteria

December 10, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CSAPG-60

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).

IPD Sharing Time Frame

After publication of main results of the study.

IPD Sharing Access Criteria

IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Peripheral Arterial Disease

Clinical Trials on cardiovascular event

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe